1. Efficacy of olanzapine and haloperidol in an animal model of mania
- Author
-
M. Adnan El-Masri, Robert S. Levy, Matthew W. Morris, Xiao-Ping Li, Sarah Decker, Mary O. Huff, and Rif S. El-Mallakh
- Subjects
Male ,Olanzapine ,Bipolar Disorder ,medicine.medical_treatment ,Haloperidol Decanoate ,Pharmacology ,Open field ,Ouabain ,Rats, Sprague-Dawley ,Benzodiazepines ,medicine ,Haloperidol ,Animals ,Drug Interactions ,Enzyme Inhibitors ,Antipsychotic ,Biological Psychiatry ,Analysis of Variance ,Behavior, Animal ,business.industry ,Dopamine antagonist ,Rats ,Disease Models, Animal ,Exploratory Behavior ,Drug Evaluation ,medicine.symptom ,business ,Mania ,Antipsychotic Agents ,medicine.drug - Abstract
Purpose Intracerebroventricular (ICV) administration of ouabain, a potent sodium pump inhibitor, has been used to model mania. Antipsychotic agents have demonstrated efficacy in the management of acute mania. This study was undertaken to determine the prophylactic efficacy of olanzapine and haloperidol in the ouabain mania model. Methods Male Sprague–Dawley rats (4–8/group) were treated with two haloperidol decanoate intramuscular shots one week apart (21 mg/kg) or twice daily olanzapine intraperitoneal injections at low dose (1 mg/kg/day) or high dose (6 mg/kg/day) for 7 days prior to ICV administration of ouabain. Open field locomotion was quantified at baseline and after ouabain administration. Results Ouabain caused a significant increase in open field locomotion (253.7 ± SEM 55.12 vs control 53.1 ± 12.13 squares traversed in 30 min in the olanzapine experiments, P
- Published
- 2006
- Full Text
- View/download PDF